HeparDxTM is an investigational MASH (NASH) activity and liver fibrosis blood test designed to diagnose and stage patients, detect at-risk MASH and monitor treatment response to therapy , /PRNewswire/ -- PR Newswire – MetaDeq Ltd. and MetaDeq Diagnostics, Inc., a private medical diagnostic company developing tests for MASH (fatty liver) and liver fibrosis, announced that two posters will be presented at the European Association for the Study of the Liver (EASL) Congress 2024, being held in .
The presented data shed new light on the PLIN2 component of the HeparDxTM diagnostic blood test and provide a further understanding of PLIN2's mechanism of action for detecting MASH. The abstracts can be found on the EASL website at and will be available for viewing on at 8 :30am CEST. HeparDxTM is able to identify and quantify inflammation and ballooning in blood monocytes with high accuracy and correlation to liver cells as assessed by liver biopsy.
This detection appears to be liver-specific and not associated with inflammation seen in subjects with cardiovascular disease (CVD). There is a clear unmet medical need to improve accuracy for non-invasive tests (NITs) for MASH. HeparDxTM is a blood test comprised of two biomarkers, one for inflammation and ballooning associated with MASH activity (PLIN2), and one for liver fibrosis (RAB14).
MetaDeq believes its diagnostic blood test ultimately may enable physicians to: 1. Diagnose MASH patients before significant disease progression occur.
